title: Adrenal suppression and osteoporosis after treatment of nasal polyposis.
abstract: CONCLUSIONS
  Patients with severe nasal polyposis (NP) and a high steroid consumption have a high prevalence of glucocorticoid-induced osteoporosis and secondary adrenal insufficiency.
  
  
  OBJECTIVE
  To evaluate the risk of complications of the medical treatment in patients presenting with the diagnosis of NP.
  
  
  METHODS
  This was a prospective study. A total of 46 consecutive patients with NP were included when the oral steroid consumption during the past year was greater than three short courses of systemic steroid treatment (i.e. more than 21 days per year of treatment, prednisolone 1 mg/kg body weight per day, for 6-10 days). The nasal function was checked on the basis of five criteria: nasal obstruction, anterior rhinorrhea, posterior rhinorrhea, facial pain, and loss of sense of smell. Two tests were carried out for each patient: (i) a bone mineral density evaluation by dual energy X-ray absorptiometry (DXA) at three different sites in the lumbar spine and femur, and (ii) an evaluation of the hypothalamic-pituitary-adrenal (HPA) axis by the synacthen test.
  
  
  RESULTS
  Most of the patients had a severe NP associated with asthma (78.3% of the population), and aspirin idiosyncrasy (28.3%). In all, 10.9% and 43.5% of patients had osteoporosis and osteopenia at the lumbar spine site. Twenty patients (48.8% of the tested patients) had an asymptomatic adrenal insufficiency.
authors.affiliation: Department of ENT-Head and Neck Surgery, European Hospital Georges Pompidou, Faculty of Medicine, University Paris-Descartes, Paris, France. pierre.bonfils@egp.aphp.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Bonfils
authors.forename: Philippe
authors.initials: P
authors.lastname: Halimi
authors.forename: David
authors.initials: D
authors.lastname: Malinvaud
mesh_terms: D015502:Absorptiometry, Photon; D000309:Adrenal Insufficiency / Q000139:chemically induced* / Q000175:diagnosis; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000175:diagnosis / Q000188:drug therapy*; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone